Daawaynta melanoma horumarsan, horumarku wuxuu ahaa nooc cusub oo immunotherapy ah, kaas oo sidoo kale Poland lagu isticmaalo koox bukaanno ah oo la soo xulay, khubaradu waxay ku wargeliyeen shir jaraa'id oo Warsaw ah.
Madaxa kiliinikada unugyada jilicsan, kansarka lafaha iyo melanoma ee Xarunta Oncology ee Warsaw, prof. Piotr Rutkowski ayaa sheegay in ilaa dhawaan, bukaanada qaba melanoma sare ay noolaan karaan oo kaliya nus sano. Thanks to immunotherapy-ga cusub, kaas oo xannibaya barnaamijka PD-1 ee soo-dhowaynta dhimashada oo dhaqaajiya nidaamka difaaca si uu ula dagaallamo unugyada kansarka, kala badh bukaannada ayaa noolaada 24 bilood. Qaar ka mid ah waxay nool yihiin in ka badan.
Daawooyinka xannibaya soo-dhoweeyaha PD-1 waxaa laga diiwaangaliyay Midowga Yurub, laakiin weli Poland laguma soo celiyo. Si kastaba ha ahaatee, waxaa laga heli karaa inta badan dalalka Yurub, oo ay ku jiraan. Slovakia, Sweden, Czech Republic, Finland, Slovenia, Bulgaria, Ireland, Spain, Denmark, Luxembourg, Austria, Greece iyo Great Britain. Ka baxsan Midowga Yurub, daawooyinkan sidoo kale waxaa lagu bixiyaa Maraykanka, Kanada, Israel iyo Switzerland.
"Waxaan sugeynaa bixinta kharashka diyaargarowgan, sababtoo ah iyaga la'aantood way adagtahay in laga hadlo daaweynta casriga ah ee melanoma metastatic, taas oo siinaya bukaanada qaarkood rajo weyn oo loogu talagalay kordhinta nolosha iyo hagaajinta tayada" - wuxuu ku nuuxnuuxsaday Prof. Rutkowski. Daawooyinkani guud ahaan ma keenaan waxyeelo kale oo halis ah.
Ilaa hadda, Hay'adda Qiimaynta Tignoolajiyada Caafimaadka iyo Tarifyada ayaa soo saartay ra'yi togan oo ku saabsan dib u bixinta dawooyinka xannibaya PD-1 ee hoos yimaada barnaamijka daroogada oo ay weheliso daawaynta kale ee loo oggolaaday daaweynta cudurkan.
Si kastaba ha ahaatee, diyaargarowga furitaanka PD-1 reseptor ayaa, si kastaba ha ahaatee, lagu isticmaalo waddankeena, ilaa hadda koox bukaan ah oo la doortay. Prof. Rutkowski ayaa sheegay in cudurka melanoma, ilaa hadda loo adeegsaday in ka badan 200 bukaan, kuwaas oo 100 ka mid ah ay weli nool yihiin. Waxaa loola dhaqmay sidii qayb ka mid ah tijaabooyinka bukaan-socodka ama waxa loogu yeero Barnaamijka Daawaynta Hore ee Helitaanka oo ay maalgeliso soo saaraha daroogada.
“Barnaamijkan, oo bilaabmay bishii Maarso 2015, waxa lagu qoray 61 bukaan oo qaba melanoma metastatic. Kooxdan, 30 bukaan ayaa weli la daweeyaa "- Prof. Rutkowski ayaa yiri.
La-taliyaha qaranka ee goobta daaweynta kansarka kansarka prof. Maciej Krzakowski, oo ah madaxa rugta kansarka sambabada ee Xarunta Oncology ee Warsaw, ayaa sheegay in dawooyinka xannibaya daawada PD-1 ee Maraykanka iyo Midowga Yurub ayaa sidoo kale loo oggolaaday daaweynta kansarka sanbabada. Poland gudaheeda, waxay hadda diyaar u yihiin oo kaliya qayb ka mid ah tijaabooyinka caafimaad.
"Ilaa hadda, daawooyinka noocan ah waxaa loo isticmaali jiray oo kaliya sida daawaynta xigta (marxaladda III), marka xulashooyinka kale ee daaweynta ay hore u daalan yihiin. Hadda isticmaalkooda daaweynta safka koowaad ayaa la tixgelinayaa "- Prof. Krzakowski ayaa yiri. Tani waxay bedeshaa istiraatijiyadda daaweynta cudurada sida melanoma horumarsan (marxaladda IV ama aan shaqaynayn, heerka III).
Prof. Krzakowski ayaa sharaxay in kansar badan ay iska ilaaliyaan weerarka unugyada difaaca bukaanka. Waxay joojiyaan ficilka PD-1 reseptor ee dusha unugyadaas (lymphocytes). Waxay adeegsadaan hab uu jidhku isticmaalo si uu uga ilaaliyo hab-dhiska difaaca inuu u dhaqmo si xad-dhaaf ah (kaas oo ka ilaalinaya cudurrada difaaca jirka).
"Daawooyinka jiilka soo socda waxay furaan PD-1 reseptors, oo u hawlgeliya habka difaaca si ay si fiican u aqoonsadaan oo loola dagaallamo unugyada kansarka," ayuu yiri lataliye qaran.
Khubaradu waxa ay qirteen intii uu socday kulanka suxufiyiinta in aanay wali jirin hab lagu go’aamin karo bukaanka ka faa’iidaysan doona noocaan ah daawaynta difaaca jirka. Xaaladda melanoma, bukaanada leh muujinta sare ee PD-1 reseptors guud ahaan waxay si fiican uga jawaabaan. Bishii Disembar 2015, mid ka mid ah daawooyinkan ayaa sidoo kale loo oggolaaday daawaynta kansarka kelyaha ee Mareykanka.
Prof. Krzakowski wuxuu sheegay in xalka wanaagsan uu noqon doono in miisaaniyada gobolka lagu maalgeliyo daawaynta noocaan ah marka ay noqoto mid waxtar u leh bukaanka la siiyay. Intaa waxaa dheer, waxaa sidoo kale jirta fursad ah in muddo ka dib daaweynta noocan oo kale ah laga yaabo in la joojiyo ugu yaraan bukaannada qaarkood, marka habka difaaca jirka uu awood u yeelan doono inuu xakameeyo horumarinta cudurka neoplastic laftiisa.
Bulshada Maraykanka ee Oncology Clinical (ASCO) bishii Febraayo 2016 waxay aqoonsan tahay immunotherapy (furitaanka PD-1 reseptor) sida guusha ugu weyn ee kansarka 2015. Tani waxaa lagu soo warramey warbixinta sanadlaha ah ee 11th "Horumarinta Kansarka Kiliinikada 2016". Immunotherapy waxay noqon doontaa mid ka mid ah mawduucyada ugu muhiimsan ee shirweynaha sanadlaha ah ee AZSCO, kaas oo ka bilaaban doona Chicago dhamaadka May.